FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 1.90% for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2015-08-11
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2015-03-31 was 1.90%, a 13.64% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2014-03-31 was 2.20%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2013-09-30 was 2.13%.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2013-06-30 was 1.20%, a 6.19% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|---|
| 2015-06-30 | 1.90% 10-Q · filed 2015-08-11 | ||||
| 2015-03-31 | 1.90% 10-Q · filed 2015-05-15 | ||||
| 2014-12-31 | 0.67% 10-Q · filed 2015-05-15 | ||||
| 2014-09-30 | 2.15% 10-Q · filed 2014-11-13 | ||||
| 2014-06-30 | 2.10% 10-Q · filed 2014-08-11 | ||||
| 2014-03-31 | 2.20% 10-Q · filed 2014-05-15 | ||||
| 2013-09-30 | 2.13% 10-Q · filed 2013-11-18 | 2.13% 10-Q · filed 2014-11-13 | 1.20% 10-Q · filed 2013-11-18 | ||
| 2013-06-30 | 1.20% 10-Q · filed 2013-08-09 | 1.20% 10-Q · filed 2014-08-11 | |||
| 2012-09-30 | 1.13% 10-Q · filed 2013-11-18 | ||||
| 2012-06-30 | 1.13% 10-Q · filed 2013-08-09 | ||||
| 2011-09-30 | 1.43% 10-Q · filed 2012-11-14 | ||||
| 2011-06-30 | 2.50% 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |